Lv3
318 积分 2024-09-07 加入
Real-world experience with extended deucravacitinib-biologic combination therapy in refractory psoriasis and psoriatic arthritis
26天前
已完结
Large‐scale meta‐analysis of infection risk with JAK – STAT inhibitors in 29,000 patients
2个月前
已完结
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial
5个月前
已完结
Deucravacitinib Inhibits Synovial Fibroblast Activation Via TYK2/STAT3 and PI3K/Akt Signaling Pathway
5个月前
已完结
TYK2 mediates neuroinflammation in Alzheimer’s disease brains with TDP-43 pathology
6个月前
已完结
Deucravacitinib-induced cutaneous hypersensitivity reactions
6个月前
已完结
A Review of Phase III and Long‐Term Data for Deucravacitinib for Plaque Psoriasis
6个月前
已完结
Targeted protein degradation in autoimmune diseases: from mechanisms to therapeutic breakthroughs
6个月前
已完结
Dermatomyositis: Clinical features and pathogenesis
6个月前
已完结
Dermatomyositis: Clinical features and pathogenesis
7个月前
已完结
皖公网安备34019202002308
